Why Novavax, Inc. Stock Just Imploded : madison

As it stated in madison

Why Novavax, Inc. Stock Just Imploded

Why Novavax, Inc. Stock Just Imploded

Already a subscriber?Click on the button below to set up your account or log in if you already have one.


moreover from seekingalpha

Novavax: Take Your Ball And Go Home - Novavax, Inc. (NASDAQ:NVAX)

Novavax: Take Your Ball And Go Home - Novavax, Inc. (NASDAQ:NVAX)

Don't go buying for a bounce or chasing, we think things can actually get worse from here for NVAX.By Parke ShallNovavax (NASDAQ:NVAX) shareholders got the news that nobody invested in a biotech wants to get yesterday when they found out that the company's latest trial for its respiratory syncytial virus (RSV) vaccine did not meet its primary endpoint.These types of trials are often all biotech companies have to go on and along those lines, NVAX ask lost nearly 90% of its market cap yesterday after the news was released.


besides smarteranalyst

Analysts Weigh In on Two Falling Biotech Stocks: Novavax, Inc. (NVAX) and XOMA Corp (XOMA)

Analysts Weigh In on Two Falling Biotech Stocks: Novavax, Inc. (NVAX) and XOMA Corp (XOMA)

Analysts are weighing in on Novavax, Inc. (NASDAQ:NVAX) and XOMA Corp (NASDAQ:XOMA), as shares of both companies fell sharply today due to various challenges and clinical trial setbacks.Let's take a closer look:Novavax, Inc.Novavax shares are crashing close to 83% today after the vaccine maker posted results last night revealing its respiratory syncytial virus (RSV) virus vaccine failed a pivotal study in the elderly, with rates considerably lower than anticipated.In reaction, Wedbush analyst Heather Behanna downgrades Novavax shares from an Outperform to a Neutral rating, while winding the price target down from $14 down to $2, a reflection of removing the elderly opportunity from the model "pending more clarity."Behanna is confused by the fluctuations of the vaccine shown in the elderly, adding, "Although we believe the RSV vaccine is viable, we have removed the elderly opportunity from our valuation at this time, pending a path forward; we step to the sidelines and downgrade shares to NEUTRAL."The next question: What next for this biotech firm as they confront this significant setback?